Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASGR1 | P07306 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13010608 | 0.83 | CA14 (0.35) | ASGR1HDAC6HDAC1HDAC2 | |
| SCHEMBL7606626 | 0.83 | HDAC6 (0.33) | ASGR1HDAC6HDAC1HDAC2 | |
| SCHEMBL15908023 | 0.82 | CTSD (0.34) | ASGR1HDAC6HDAC1HDAC2CTSD | |
| SCHEMBL12209106 | 0.82 | ASGR1 (0.39) | ASGR1HDAC6HDAC1HDAC2CTSD | |
| SCHEMBL22946716 | 0.81 | — | — | |
| SCHEMBL7610203 | 0.81 | ASGR1 (0.33) | ASGR1HDAC6HDAC1HDAC2CTSD | |
| SCHEMBL29818922 | 0.81 | ASGR1 (0.33) | ASGR1HDAC6HDAC1HDAC2CTSD | |
| SCHEMBL23562270 | 0.79 | ASGR1 (0.32) | ASGR1HDAC6HDAC1HDAC2CTSD | |
| SCHEMBL7608850 | 0.79 | ASGR1 (0.35) | ASGR1HDAC6HDAC1HDAC2CTSD | |
| SCHEMBL23539397 | 0.78 | GRM1 (0.34) | ASGR1HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078202-B2 | β-lactamase inhibitor and use thereof | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-20210032260-A1 | Beta-lactamase inhibitor and use thereof | Evopoint Biosciences Co., Ltd. (CN) | 2021-02-04 | — | — | US | disclosed |
| EP-2881384-B1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-1170281-B1 | 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof | SERVIER LAB (FR) | 2005-12-21 | — | — | EP | disclosed |
| US-6943184-B2 | 1,1- and 1,2-disubstituted cyclopropane compounds | LES LABORATORIES SERVIER (FR) | 2005-09-13 | — | — | US | disclosed |
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | ADIR ET COMPAGNIE (FR) | 2002-02-21 | — | — | US | disclosed |
| EP-1170281-A1 | 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof | LES LABORATOIRES SERVIER (FR) | 2002-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032260-A1 | Beta-lactamase inhibitor and use thereof | CYP51A1, LCT, CEL | ASGR1 2449/4885HDAC6 1546/4885HDAC1 986/4885 |
| US-11078202-B2 | β-lactamase inhibitor and use thereof | CYP51A1, LCT, CEL | ASGR1 2518/4885HDAC6 1470/4885HDAC1 954/4885 |
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | HCAR1, CHRNA1, CNR1 | ASGR1 89/4885HDAC6 2547/4885HDAC1 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.